Atlas Venture's Quartet aims to harness the immune system to make painkillers

While one of the hottest areas of cancer drug development is based on an approach that uses the body's immune system, a handful of investors are making a $17 million bet on a Cambridge biotech aiming to take a similar approach to pain management...
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.